157 related articles for article (PubMed ID: 23408495)
21. Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis.
Bae EK; Lee J; Shin JW; Moon J; Lee KJ; Shin YW; Kim TJ; Shin D; Jang IJ; Lee SK
Seizure; 2016 Apr; 37():8-12. PubMed ID: 26908152
[TBL] [Abstract][Full Text] [Related]
22. Factors affecting antiepileptic drug pharmacokinetics in community-dwelling elderly.
Cloyd JC; Marino S; Birnbaum AK
Int Rev Neurobiol; 2007; 81():201-10. PubMed ID: 17433925
[TBL] [Abstract][Full Text] [Related]
23. Population pharmacokinetic modelling of carbamazepine by using the iterative Bayesian (IT2B) and the nonparametric EM (NPEM) algorithms: implications for dosage.
Bondareva IB; Sokolov AV; Tischenkova IF; Jelliffe RW
J Clin Pharm Ther; 2001 Jun; 26(3):213-23. PubMed ID: 11422606
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic interactions of carbamazepine with some antiepileptic drugs during epilepsy treatment in children and adolescents.
Steinborn B
Rocz Akad Med Bialymst; 2005; 50 Suppl 1():9-15. PubMed ID: 16119616
[TBL] [Abstract][Full Text] [Related]
25. Effects of CYP3A5 and UGT2B7 variants on steady-state carbamazepine concentrations in Chinese epileptic patients.
Lu Q; Huang YT; Shu Y; Xu P; Xiang DX; Qu Q; Qu J
Medicine (Baltimore); 2018 Jul; 97(30):e11662. PubMed ID: 30045320
[TBL] [Abstract][Full Text] [Related]
26. Polymorphic Variants of SCN1A and EPHX1 Influence Plasma Carbamazepine Concentration, Metabolism and Pharmacoresistance in a Population of Kosovar Albanian Epileptic Patients.
Daci A; Beretta G; Vllasaliu D; Shala A; Govori V; Norata GD; Krasniqi S
PLoS One; 2015; 10(11):e0142408. PubMed ID: 26555147
[TBL] [Abstract][Full Text] [Related]
27. Daily fluctuation of plasma levels with conventional and controlled-release carbamazepine: correlation with adverse effects.
Bareggi SR; Tata MR; Guizzaro A; Pirola R; Parisi A; Monza CG
Int Clin Psychopharmacol; 1994; 9(1):9-16. PubMed ID: 8195585
[TBL] [Abstract][Full Text] [Related]
28. Factors influencing plasma concentrations of carbamazepine and carbamazepine-10,11-epoxide in epileptic children and adults.
Lanchote VL; Bonato PS; Campos GM; Rodrigues I
Ther Drug Monit; 1995 Feb; 17(1):47-52. PubMed ID: 7725376
[TBL] [Abstract][Full Text] [Related]
29. Effect of Piperine on the Metabolism and Pharmacokinetics of Carbamazepine in Healthy Volunteers.
Bedada SK; Appani R; Boga PK
Drug Res (Stuttg); 2017 Jan; 67(1):46-51. PubMed ID: 27776366
[TBL] [Abstract][Full Text] [Related]
30. Carbamazepine drug interactions: the influence of concurrent drug therapy on serum concentrations of carbamazepine and its epoxide metabolite.
Wang RB; Liu LT; Yiu CH; Chang TY
Zhonghua Yi Xue Za Zhi (Taipei); 1990 Apr; 45(4):222-32. PubMed ID: 2168269
[TBL] [Abstract][Full Text] [Related]
31. Lack of interaction of gabapentin with carbamazepine or valproate.
Radulovic LL; Wilder BJ; Leppik IE; Bockbrader HN; Chang T; Posvar EL; Sedman AJ; Uthman BM; Erdman GR
Epilepsia; 1994; 35(1):155-61. PubMed ID: 8112239
[TBL] [Abstract][Full Text] [Related]
32. Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on dose-adjusted plasma levels of carbamazepine in epileptic patients in South Indian population.
Ganesapandian M; Ramasamy K; Adithan S; Narayan SK
Indian J Pharmacol; 2019; 51(6):384-388. PubMed ID: 32029960
[TBL] [Abstract][Full Text] [Related]
33. Kinetic profile of carbamazepine in an adult Portuguese outpatient population.
Almeida AM; Falcão AC; Sales F; Leitão F; Santos J; Costa IM; Caramona MM
J Clin Pharm Ther; 1998 Aug; 23(4):315-21. PubMed ID: 9867316
[TBL] [Abstract][Full Text] [Related]
34. Predictability of individualized dosage regimens of carbamazepine and valproate mono- and combination therapy.
Bondareva IB; Jelliffe RW; Andreeva OV; Bondareva KI
J Clin Pharm Ther; 2011 Oct; 36(5):625-36. PubMed ID: 21062333
[TBL] [Abstract][Full Text] [Related]
35. Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy.
Puranik YG; Birnbaum AK; Marino SE; Ahmed G; Cloyd JC; Remmel RP; Leppik IE; Lamba JK
Pharmacogenomics; 2013 Jan; 14(1):35-45. PubMed ID: 23252947
[TBL] [Abstract][Full Text] [Related]
36. Developmental and therapeutic pharmacology of antiepileptic drugs.
Miura H
Epilepsia; 2000; 41 Suppl 9():2-6. PubMed ID: 11156504
[TBL] [Abstract][Full Text] [Related]
37. Comparison of equations for predicting bound serum concentrations of carbamazepine and carbamazepine-10, 11-epoxide after polytherapy in patients with epilepsy.
Kodama Y; Kuranari M; Kodama H; Tsutsumi K; Fujii I; Takeyama M
J Clin Pharmacol; 1995 Oct; 35(10):995-1002. PubMed ID: 8568018
[TBL] [Abstract][Full Text] [Related]
38. Usefulness of salivary drug monitoring for detecting efflux transporter overexpression.
Fagiolino P; Vázquez M; Maldonado C; Ruiz ME; Volonté MG; Orozco-Suárez S; Lazarowski A
Curr Pharm Des; 2013; 19(38):6701-8. PubMed ID: 23530513
[TBL] [Abstract][Full Text] [Related]
39. Adjustment of carbamazepine dose to offset the effects of the interaction with remacemide hydrochloride in a double-blind, multicentre, add-on drug trial (CR2237) in refractory epilepsy.
Mawer GE; Jamieson V; Lucas SB; Wild JM
Epilepsia; 1999 Feb; 40(2):190-6. PubMed ID: 9952266
[TBL] [Abstract][Full Text] [Related]
40. Effect of vigabatrin on the pharmacokinetics of carbamazepine.
Sánchez-Alcaraz A; Quintana MB; López E; Rodríguez I; Llopis P
J Clin Pharm Ther; 2002 Dec; 27(6):427-30. PubMed ID: 12472982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
